Blue Jet Healthcare Q4 FY26: QoQ profit up, ₹1,000cr raise

Stock jumps after results and fundraise plan

Blue Jet Healthcare shares rose as much as 10% in Monday’s trade after the company reported its March-quarter numbers and outlined a plan to raise fresh capital. The stock settled at ₹483.90 on the NSE, up 9.72%. The price move followed two key disclosures: a sequential jump in quarterly profit and the board’s approval for a fundraise of up to ₹1,000 crore. Alongside the capital plan, the board also recommended a final dividend for FY26.

What drove the move in the stock

The immediate trigger for the rally was the company’s Q4 FY26 net profit of ₹64.34 crore, which marked a 60% rise from ₹40.16 crore in the December quarter. At the same time, the company indicated it is preparing to access capital markets through multiple permissible routes. Investors typically track such announcements closely because they can affect future growth plans, balance sheet flexibility, and near-term equity dilution.

Q4 FY26 profit: strong sequentially, weak year-on-year

While sequential profit improved, the year-on-year comparison was softer. Net profit for the March quarter declined 41.6% from ₹110.10 crore in Q4 FY25 (also reported as ₹110 crore in one disclosure). The company’s Q4 FY26 quarterly profit was also disclosed as ₹643.44 million, which equals ₹64.34 crore, aligning with the reported PAT number. The contrasting QoQ and YoY trends point to a stronger finish to the quarter versus Q3, but a weaker performance compared with the same period last year.

Revenue trend: sharp YoY fall in the March quarter

Revenue pressure was a key part of the quarter’s story. Revenue from operations fell 31.1% YoY to ₹234.67 crore in Q4 FY26, down from ₹340.45 crore a year earlier. Another disclosure reported total income of ₹257.59 crore for Q4 FY26 (₹2,575.88 million), indicating the quarter’s overall income including other components. The set of numbers together shows that the March quarter had a notable year-on-year contraction in the top line, even as profitability improved sequentially.

Board clears up to ₹1,000 crore fundraise

Blue Jet Healthcare’s board approved a proposal to raise up to ₹1,000 crore (also stated as ₹10,000 million) through a range of instruments and routes. The company said the issuance may be done through qualified institutional placement (QIP), preferential issue, private placement, rights issue, or other permissible methods, subject to regulatory and shareholder approvals. The board also indicated the fundraising could involve securities such as fully paid-up equity shares, fully or partly convertible debentures, convertible preference shares, or other equity-linked instruments. The approval includes the possibility of a green shoe option, as stated in one of the board updates.

EGM date set for shareholder approval

The company said it will hold an extraordinary general meeting (EGM) on June 17, 2026 to seek shareholder approval for the proposed fundraise. One disclosure specified the EGM time as 11:00 a.m. (IST) and noted it will be conducted via video conferencing. This sets a clear near-term milestone for investors watching the capital plan.

Dividend: ₹1.2 per share recommended for FY26

Blue Jet Healthcare’s board recommended a final dividend of ₹1.2 per equity share for FY26, subject to shareholders’ approval. The shares have a face value of ₹2 each, and the dividend was described as a 60% payout on face value in the disclosures. The company indicated the dividend proposal will be placed before shareholders at the next Annual General Meeting, with record and payment dates to be announced later.

FY26 headline numbers disclosed

For the financial year ended March 31, 2026, the company reported total annual income of ₹1,015.98 crore (₹10,159.75 million). Profit for the year was disclosed as ₹247.82 crore (₹2,478.16 million), with EPS of ₹14.29. Another disclosure provided revenue from operations of ₹1,029.99 crore for FY26 (₹10,299.85 million) and PBT of ₹332.51 crore (₹3,325.12 million). These are the figures the market will use to compare the company’s annual performance alongside its capital-allocation decisions.

Business context from the disclosures

Blue Jet Healthcare was described as a specialty pharmaceutical company focused on contrast media and other high-value active pharmaceutical ingredients. The company’s operations were also described as including manufacturing of artificial sweeteners, contrast media, and pharma intermediates. The fundraise, if executed, would add financial flexibility at a time when quarterly revenue and year-on-year profitability have shown pressure.

Key numbers at a glance

Market impact and what investors will track next

The combination of a sharp QoQ profit improvement and a sizeable fundraise proposal shaped the day’s trading response, with the stock closing nearly 10% higher. Over the near term, investors are likely to watch the June 17, 2026 EGM outcome and any subsequent details on the fundraising route, instrument mix, and timing. The quarter’s numbers also highlight a divergence between sequential profitability and year-on-year revenue and profit trends, keeping focus on operating performance in coming quarters.

Conclusion

Blue Jet Healthcare’s March-quarter update brought a clear set of signals: sequential profit improved to ₹64.34 crore, but YoY comparisons remained weaker, and revenue from operations fell to ₹234.67 crore. The board’s plan to raise up to ₹1,000 crore and the scheduled June 17, 2026 EGM are the next defined events on the company’s calendar. Shareholders will also vote on the ₹1.2 per share final dividend recommendation for FY26.